Trial · NCT07025590
Effect of Exercise on Tapering Antipsychotics in Patients With Psycho-cardiological Disease(EXTRA-study)
NCT07025590, Not applicable, Recruiting, Guangdong Provincial People's Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Exercise on Tapering Antipsychotics in Patients With Psycho-cardiological Disease(EXTRA-study). Trials, record NCT07025590. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07025590
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Exercise on Tapering Antipsychotics in Patients With Psycho-cardiological Disease(EXTRA-study)
- NCT number
- NCT07025590
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 106 participants, estimated
- Lead sponsor
- Guangdong Provincial People's Hospital
- Conditions
- Cardiovascular Diseases (CVD), Depression Anxiety Disorder
- Interventions
- Moderate-intensity continuous movement and Antipsychotics intervention, Antipsychotics intervention(sertraline, escitalopram, fluoxetine, duloxetine, paroxetine, venlafaxine, and fluvoxamine)
- First posted
- 2025-06-17
- Last updated
- 2025-06-17
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dosage of anti-anxiety/depression drugs | Baseline and after 12 weeks of intervention | The proportion of patients with cardiovascular diseases complicated with anxiety and depression who received a 50% reduction in the dosage of anti-anxiety/depression drugs |
| Secondary | Hamilton Depression and Anxiety Scale (HAMD, HAMA) | Baseline and at the end of the intervention (Week 12), 1 month, 6 months, 1 year and 2 years after the end of the intervention | HAMD：0-76 points; HAMA: 0-56 points The higher the score is, the worse the result will be |
| Secondary | Perceived Stress Scale (PSS) | Baseline and at the end of the intervention (Week 12), 1 month, 6 months, 1 year and 2 years after the end of the intervention | PSS: 0-40 points The higher the score is, the worse the result will be |
| Secondary | Pittsburgh Sleep Quality Index (PSQI) | Baseline and at the end of the intervention (Week 12), 1 month, 6 months, 1 year and 2 years after the end of the intervention | PSQI: 0-21 points the higher the score, the worse the result. |
| Secondary | 12-Item Short Form Health Survey（SF-12） | Baseline and at the end of the intervention (Week 12), 1 month, 6 months, 1 year and 2 years after the end of the intervention | SF-12:0-100 points. The higher the score, the better the health condition |
| Secondary | Discontinuation Emergent Symptoms and Signs Scale（DESS） | Baseline and at the end of the intervention (Week 12), 1 month, 6 months, 1 year and 2 years after the end of the intervention | The more new symptoms emerge, the more severe the adverse reactions of drug withdrawal will be. |
| Secondary | Cardiopulmonary exercise test（CPET） | Baseline and at the end of the intervention (Week 12), one month after the end of the intervention | |
| Secondary | The recurrence rate of anxiety/depression | Baseline and one month, six months, one year and two years after the intervention ended | |
| Secondary | Electrocardiogram | Baseline and at the end of the intervention (Week 12), one month after the end of the intervention | Evaluate QTc |
| Secondary | Blood test | Baseline and at the end of the intervention (Week 12) | Liver function, seven items of blood lipid, two items of myocardial function, blood routine, biochemical indicators |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07025590
GET https://conductscience.org/api/trials/v1/NCT07025590/registered